VBIO · Valion Bio, Inc. · Documents
$1.21
+0.05 (+4.31%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current cash levels and burn rate, amongst other things, the Company believes its cash and financial resources may be insufficient to meet the Company's anticipated needs for the twelve months following the date of issuance of the financial statements for the six months ended June 30, 2026, included elsewhere in this Report, which raises substantial doubt about the Company's ability to continue as a going concern within one year from the issuance date of the financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.02M
Shares
887,590
Volume · Oct 20
57.17K
Avg daily vol (36 sessions)
2.39M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| DEF 14A | Valion Bio is holding a virtual Special Meeting on November 12, 2026 to seek stockholder approval of a reverse stock split between 1-for-2 and 1-for-12, an increase of 272,000 shares under its 2021 Equity Incentive Plan, and adjournment authority. The Board recommends voting FOR each proposal. | 2026-10-16 | 2026-11-12 | |
| S-3 | Valion Bio filed a prospectus for selling stockholder 3i, LP's resale of up to 3,954,381 common shares issuable upon conversion of Series B and Series C preferred stock and warrant exercise. The stock trades on Nasdaq as "VBIO." | 2026-10-16 | — | |
| 8-K | Valion Bio, Inc. said Velocity Bioworks completed an initial feasibility evaluation of LarmorBio’s BioScan-NMR™ platform, finding a strong correlation with optical density at 600 nm (OD600) that supports continued development for non-invasive fermentation monitoring. | 2026-10-15 | — | |
| 8-K | Valion Bio, Inc. highlighted wholly owned Velocity Bioworks’ San Antonio capabilities for process development, analytical services and early-phase clinical drug substance manufacturing, including GMP microbial manufacturing at scales up to 200 liters. | 2026-10-14 | — | |
| S-3 | — | 2026-10-08 | — | |
| 8-K | — | 2026-10-08 | 2026-10-07 | |
| 8-K | — | 2026-10-06 | 2026-10-05 | |
| PRE 14A | — | 2026-10-02 | — | |
| 8-K | — | 2026-10-01 | 2026-09-30 | |
| 8-K | — | 2026-09-23 | 2026-09-17 | |
| 8-K | — | 2026-09-01 | 2026-08-27 | |
| 8-K | — | 2026-08-27 | 2026-08-26 | |
| 8-K/A | — | 2026-08-20 | 2026-08-14 | |
| 8-K | — | 2026-08-17 | 2026-08-14 | |
| 10-Q | — | 2026-08-14 | 2026-06-30 | |
| 8-K | — | 2026-08-06 | 2026-07-31 | |
| S-1 | — | 2026-07-17 | — | |
| DEF 14A | — | 2026-07-17 | 2026-08-14 | |
| 8-K | — | 2026-07-14 | — | |
| PRE 14A | — | 2026-07-07 | 2026-08-14 | |
| 8-K | — | 2026-06-18 | 2026-06-17 | |
| 8-K | — | 2026-06-03 | 2026-05-28 | |
| 10-Q | — | 2026-05-14 | 2026-03-31 | |
| 8-K | — | 2026-05-14 | — | |
| 8-K | — | 2026-05-04 | 2026-05-01 | |
| ARS | — | 2026-04-30 | 2025-12-31 | |
| DEF 14A | — | 2026-04-30 | 2026-05-28 | |
| 8-K | — | 2026-04-23 | 2026-04-22 | |
| PRE 14A | — | 2026-04-20 | 2026-04-17 | |
| S-1 | — | 2026-04-13 | — | |
| 10-K | — | 2026-03-30 | 2025-12-31 | |
| 8-K | — | 2026-03-25 | — | |
| 8-K | — | 2026-03-20 | 2026-03-19 | |
| 8-K | — | 2026-03-13 | 2026-03-09 | |
| 8-K | — | 2026-03-11 | — | |
| 8-K | — | 2026-03-04 | 2026-03-02 | |
| 8-K/A | — | 2026-02-23 | 2025-12-09 | |
| 8-K | — | 2026-02-09 | 2026-02-06 | |
| DEFA14A | — | 2026-02-09 | — | |
| 8-K | — | 2026-01-20 | — | |
| DEF 14A | — | 2026-01-09 | — | |
| PRE 14A | — | 2025-12-29 | — | |
| S-3 | — | 2025-12-29 | — | |
| S-3 | — | 2025-12-29 | — | |
| 8-K | — | 2025-12-11 | 2025-12-09 | |
| 8-K | — | 2025-11-18 | — | |
| 8-K | — | 2025-11-14 | 2025-11-12 | |
| 10-Q | — | 2025-11-14 | 2025-09-30 | |
| 8-K | — | 2025-11-13 | — | |
| S-3 | — | 2025-10-17 | — |
Showing 1–50 of 180 filings